Targeting hepatic macrophages to treat liver diseases
- PMID: 28267621
- DOI: 10.1016/j.jhep.2017.02.026
Targeting hepatic macrophages to treat liver diseases
Abstract
Our view on liver macrophages in the context of health and disease has been reformed by the recognition of a remarkable heterogeneity of phagocytes in the liver. Liver macrophages consist of ontogenically distinct populations termed Kupffer cells and monocyte-derived macrophages. Kupffer cells are self-renewing, resident and principally non-migratory phagocytes, serving as sentinels for liver homeostasis. Liver injury triggers Kupffer cell activation, leading to inflammatory cytokine and chemokine release. This fosters the infiltration of monocytes into the liver, which give rise to large numbers of inflammatory monocyte-derived macrophages. Liver macrophages are very plastic and adapt their phenotype according to signals derived from the hepatic microenvironment (e.g. danger signals, fatty acids, phagocytosis of cellular debris), which explains their manifold and even opposing functions during disease. These central functions include the perpetuation of inflammation and hepatocyte injury, activation of hepatic stellate cells with subsequent fibrogenesis, and support of tumor development by angiogenesis and T cell suppression. If liver injury ceases, specific molecular signals trigger hepatic macrophages to switch their phenotype towards reparative phagocytes that promote tissue repair and regression of fibrosis. Novel strategies to treat liver disease aim at targeting macrophages. These interventions modulate Kupffer cell activation (e.g. via gut-liver axis or inflammasome formation), monocyte recruitment (e.g. via inhibiting chemokine pathways like CCR2 or CCL2) or macrophage polarization and differentiation (e.g. by nanoparticles). Evidence from mouse models and early clinical studies in patients with non-alcoholic steatohepatitis and fibrosis support the notion that pathogenic macrophage subsets can be successfully translated into novel treatment options for patients with liver disease.
Lay summary: Macrophages (Greek for "big eaters") are a frequent non-parenchymal cell type of the liver that ensures homeostasis, antimicrobial defense and proper metabolism. However, liver macrophages consist of different subtypes regarding their ontogeny (developmental origin), differentiation and function. Understanding this heterogeneity and the critical regulation of inflammation, fibrosis and cancer by macrophage subsets opens promising new options for treating liver diseases.
Keywords: Chemokine; Cholestasis; HBV; HCC; HCV; Kupffer cell; Liver fibrosis; Macrophage; Monocyte; NASH.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.Hepatology. 2018 Apr;67(4):1270-1283. doi: 10.1002/hep.29544. Epub 2018 Feb 19. Hepatology. 2018. PMID: 28940700
-
Macrophage heterogeneity in liver injury and fibrosis.J Hepatol. 2014 May;60(5):1090-6. doi: 10.1016/j.jhep.2013.12.025. Epub 2014 Jan 8. J Hepatol. 2014. PMID: 24412603 Review.
-
Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases.Front Immunol. 2019 Dec 3;10:2852. doi: 10.3389/fimmu.2019.02852. eCollection 2019. Front Immunol. 2019. PMID: 31849997 Free PMC article. Review.
-
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice.Hepatology. 2014 Mar;59(3):1060-72. doi: 10.1002/hep.26783. Epub 2014 Jan 30. Hepatology. 2014. PMID: 24481979
-
Macrophage Phenotype and Function in Liver Disorder.Front Immunol. 2020 Jan 28;10:3112. doi: 10.3389/fimmu.2019.03112. eCollection 2019. Front Immunol. 2020. PMID: 32047496 Free PMC article. Review.
Cited by
-
Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes.J Extracell Vesicles. 2021 May;10(7):e12109. doi: 10.1002/jev2.12109. Epub 2021 May 24. J Extracell Vesicles. 2021. PMID: 34084287 Free PMC article.
-
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.J Hepatol. 2021 Jul;75 Suppl 1(Suppl 1):S49-S66. doi: 10.1016/j.jhep.2021.01.002. J Hepatol. 2021. PMID: 34039492 Free PMC article. Review.
-
Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin αvβ6 upregulation following liver injury.J Clin Invest. 2021 May 3;131(9):e132305. doi: 10.1172/JCI132305. J Clin Invest. 2021. PMID: 33724957 Free PMC article.
-
The Dual Role of Innate Immune Response in Acetaminophen-Induced Liver Injury.Biology (Basel). 2022 Jul 14;11(7):1057. doi: 10.3390/biology11071057. Biology (Basel). 2022. PMID: 36101435 Free PMC article. Review.
-
Construction and drug screening of Co-culture system using extrahepatic cholangiocarcinoma organoids and tumor-associated macrophages.Heliyon. 2024 Aug 23;10(17):e36377. doi: 10.1016/j.heliyon.2024.e36377. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263166 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical